Fundraising FoxLupeng Pharmaceutical
3 known investors
Find your way into Lupeng Pharmaceutical
Sign up to see every warm intro you have to Lupeng Pharmaceutical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lupeng Pharmaceutical team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
Founders & leadership
周
周正清首席财务官 (CFO)
SA
Stephen Anthony首席医学官 (Chief Medical Officer)
Investors · 3
Frequently asked questions
- What does Lupeng Pharmaceutical do?
- Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
- Who are Lupeng Pharmaceutical's investors?
- Lupeng Pharmaceutical's investors include LAV, Lilly Asia Ventures, OrbiMed.